Detalles de la búsqueda
1.
Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials.
Oncologist
; 29(5): 422-430, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38349736
2.
Differential Protein Citrullination in Human ER- and ER+ Tumor and Adjacent Healthy Breast Tissue.
Biochemistry
; 62(4): 893-898, 2023 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36757899
3.
The Development of the Oncology Center of Excellence Patient-Friendly Language Glossary of Oncology Clinical Trial Terms.
Oncologist
; 28(5): 379-382, 2023 05 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-36882084
4.
Floor and ceiling effects in the EORTC QLQ-C30 Physical Functioning Subscale among patients with advanced or metastatic breast cancer.
Cancer
; 128(4): 808-818, 2022 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34634139
5.
US Food and Drug Administration Analysis of Patient-Reported Diarrhea and Its Impact on Function and Quality of Life in Patients Receiving Treatment for Breast Cancer.
Value Health
; 25(4): 566-570, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35365300
6.
Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 22(11): 1573-1581, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34656225
7.
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.
Lancet Oncol
; 22(9): 1230-1239, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34310904
8.
Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health.
Oncologist
; 26(10): e1786-e1799, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34196068
9.
FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.
Oncologist
; 26(5): 433-438, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33687763
10.
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Oncologist
; 26(1): e164-e172, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33017510
11.
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer.
Oncologist
; 26(2): 139-146, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33145877
12.
US Food and Drug Administration regulatory updates in neuro-oncology.
J Neurooncol
; 153(3): 375-381, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34156585
13.
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Lancet Oncol
; 21(2): 250-260, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31859246
14.
Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Oncologist
; 25(4): 348-354, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32297444
15.
The Wild West of Checkpoint Inhibitor Development.
N Engl J Med
; 386(14): 1297-1301, 2022 04 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34910860
16.
The On- and Off-Ramps of Oncology Accelerated Approval.
N Engl J Med
; 387(16): 1439-1442, 2022 10 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-36129992
17.
Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: U.S. Food and Drug Administration Oncology Center of Excellence Public Workshop.
J Urol
; 203(1): 115-119, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31502940
18.
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer Immunotherapy.
Curr Oncol Rep
; 22(11): 116, 2020 08 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32851542
19.
Exploration of baseline patient-reported side effect bother from cancer therapy.
Clin Trials
; 17(3): 332-337, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32153216
20.
Patient-Friendly Language to Facilitate Treatment Choice for Patients with Cancer.
Oncologist
; 24(8): 1011-1012, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31097617